酒精相关肝细胞癌发生和发展的研究进展

摘要/Abstract

摘要： 原发性肝癌是危害全国人民健康的主要肿瘤之一,其中肝细胞癌(HCC)占其绝大部分。酒精是导致肝损伤的重要原因,其通过直接毒性及间接作用介导产生脂肪肝、肝炎、肝硬化及最终肝癌等一系列历程,并可以加重其他危险因素所致肝损伤。因此,明确酒精代谢过程及其引起肝癌的可能机制有助于探索酒精相关HCC防治的生物标记物,并指导开发新的靶点及靶向治疗策略,从而进一步促进HCC的个体化精准治疗。

关键词: 肝细胞癌, 酒精性肝病, 乙醛, 代谢

冯加其, 刘雄青, 黄鑫昱, 刘璐, 王甘露. 酒精相关肝细胞癌发生和发展的研究进展[J]. 肝脏, 2025, 30(1): 132-135.

/ 推荐

[1] KimD Y. Changing etiology and epidemiology of hepatocellular carcinoma: asia and worldwide[J]. J Liver Cancer, 2024,24(1):62-70.
[2] RumgayH, Ferlay J, de Martel C, et al. Global, regional and national burden of primary liver cancer by subtype[J]. Eur J Cancer, 2022,161:108-118.
[3] TohM R, Wong E, Wong S H, et al. Global epidemiology and genetics of hepatocellular carcinoma[J]. Gastroenterology, 2023,164(5):766-782.
[4] 高沿航. 酒精性肝病[J]. 肝脏, 2023,28(1):16-20.
[5] LieberC S. Metabolism of alcohol[J]. Clin Liver Dis, 2005,9(1):1-35.
[6] EhrmannJ, Aiglova K, Urban O, et al. Alcohol-related liver diseases (ALD)[J]. Vnitr Lek, 2020,66(5):39-51.
[7] HyunJ, Han J, Lee C, et al. Pathophysiological aspects of alcohol metabolism in the liver[J]. Int J Mol Sci, 2021,22(11).
[8] Ganne-CarrieN, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease[J]. J Hepatol, 2019,70(2):284-293.
[9] FuenzalidaC, Dufeu M S, Poniachik J, et al. Probiotics-based treatment as an integral approach for alcohol use disorder in alcoholic liver disease[J]. Front Pharmacol, 2021,12:729950.
[10] MakK M, Shekhar A C. Lipopolysaccharide, arbiter of the gut-liver axis, modulates hepatic cell pathophysiology in alcoholism[J]. Anat Rec (Hoboken), 2024.
[11] LiuH, Kang X, Yang X, et al. Compound probiotic ameliorates acute alcoholic liver disease in mice by modulating gut microbiota and maintaining intestinal barrier[J]. Probiotics Antimicrob Proteins, 2023,15(1):185-201.
[12] SubramaniyanV, Chakravarthi S, Jegasothy R, et al. Alcohol-associated liver disease: a review on its pathophysiology, diagnosis and drug therapy[J]. Toxicol Rep, 2021,8:376-385.
[13] WuX, Fan X, Miyata T, et al. Recent advances in understanding of pathogenesis of alcohol-associated liver disease[J]. Annu Rev Pathol, 2023,18:411-438.
[14] ZhangX, Shi L, Lu X, et al. Bile acids and liver cancer: molecular mechanism and therapeutic prospects[J]. Pharmaceuticals(Basel),2024: 17(9):1142.
[15] ShiX, Chang C C, Basson M D, et al. Alcohol disrupts human liver stem/progenitor cell proliferation and differentiation[J]. J Stem Cell Res Ther, 2014,4(5):205.
[16] OsnaN A, Rasineni K, Ganesan M, et al. Pathogenesis of alcohol-associated liver disease[J]. J Clin Exp Hepatol, 2022,12(6):1492-1513.
[17] YangY M, Cho Y E, Hwang S. Crosstalk between oxidative stress and inflammatory liver injury in the pathogenesis of alcoholic liver disease[J]. Int J Mol Sci, 2022,23(2):774.
[18] LiY, Yu Y, Yang L, et al. Insights into the role of oxidative stress in hepatocellular carcinoma development[J]. Front Biosci (Landmark Ed), 2023,28(11):286.
[19] NaM, Yang X, Deng Y, et al. Endoplasmic reticulum stress in the pathogenesis of alcoholic liver disease[J]. Peer J, 2023,11:e16398.
[20] Sasaki-TanakaR, Ray R, Moriyama M, et al. Molecular changes in relation to alcohol consumption and hepatocellular carcinoma[J]. Int J Mol Sci, 2022,23(17):9679.
[21] RodriguezM J, Sabaj M, Tolosa G, et al. Maresin-1 prevents liver fibrosis by targeting Nrf2 and NF-kappaB, reducing oxidative stress and inflammation[J]. Cells, 2021,10(12):3406.
[22] LiS, Tan H Y, Wang N, et al. Recent insights into the role of immune cells in alcoholic liver disease[J]. Front Immunol, 2019,10:1328.
[23] AitA Y, Lafdil F, Tacke F. Ambiguous pathogenic roles of macrophages in alcohol-associated liver diseases[J]. Hepat Med, 2023,15:113-127.
[24] SunJ, Zhao P, Shi Y, et al. Recent insight into the role of macrophage in alcohol-associated liver disease: a mini-review[J]. Front Cell Dev Biol, 2023,11:1292016.
[25] SeenS. Chronic liver disease and oxidative stress - a narrative review[J]. Expert Rev Gastroenterol Hepatol, 2021,15(9):1021-1035.
[26] WenB, Zhang C, Zhou J, et al. Targeted treatment of alcoholic liver disease based on inflammatory signalling pathways[J]. Pharmacol Ther, 2021,222:107752.
[27] LiuS Y, Tsai I T, Hsu Y C. Alcohol-related liver disease: basic mechanisms and clinical perspectives[J]. Int J Mol Sci, 2021,22(10):5170.
[28] PohlK, Moodley P, Dhanda A D. Alcohol′s impact on the gut and liver[J]. Nutrients, 2021,13(9):3170.
[29] LuY, George J. Interaction between fatty acid oxidation and ethanol metabolism in liver[J]. Am J Physiol Gastrointest Liver Physiol, 2024,326(5):G483-G494.
[30] JeonS, Carr R. Alcohol effects on hepatic lipid metabolism[J]. J Lipid Res, 2020,61(4):470-479.
[31] HagstromH, Hegmar H, Moreno C. Interactions between the metabolic syndrome and alcohol consumption increases the risk of liver disease[J]. United European Gastroenterol J, 2024,12(2):168-176.
[32] AbergF, Byrne C D, Pirola C J, et al. Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease[J]. J Hepatol, 2023,78(1):191-206.
[33] MaccioniL, Fu Y, Horsmans Y, et al. Alcohol-associated bowel disease: new insights into pathogenesis[J]. eGastroenterology, 2023,1(1):e100013.
[34] ButtsM, Sundaram V L, Murughiyan U, et al. The influence of alcohol consumption on intestinal nutrient absorption: a comprehensive review[J]. Nutrients, 2023,15(7):1571.
[35] TaniaiM. Alcohol and hepatocarcinogenesis[J]. Clin Mol Hepatol, 2020,26(4):736-741.
[36] ReggidoriN, Bucci L, Santi V, et al. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs[J]. JHEP Rep, 2023,5(8):100784.
[37] OmarM A, Omran M M, Farid K, et al. Biomarkers for hepatocellular carcinoma: from origin to clinical diagnosis[J]. Biomedicines, 2023,11(7):1852.
[38] SingalA G, Kanwal F, Llovet J M. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy[J]. Nat Rev Clin Oncol, 2023,20(12):864-884.
[39] RamkissoonR, Shah V H. Alcohol use disorder and alcohol-associated liver disease[J]. Alcohol Res, 2022,42(1):13.
[40] LiuZ, Yuan H, Suo C, et al. Point-based risk score for the risk stratification and prediction of hepatocellular carcinoma: a population-based random survival forest modeling study[J]. eClinicalMedicine, 2024,75:102796.
[41] TumenD, Heumann P, Gulow K, et al. Pathogenesis and current treatment strategies of hepatocellular carcinoma[J]. Biomedicines, 2022,10(12):3202.

酒精相关肝细胞癌发生和发展的研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王昕, 饶慧瑛. 代谢相关脂肪性肝病合并肝硬化治疗的挑战与未来前景[J]. 肝脏, 2025, 30(1): 4-6.
[2]	李强, 陈良. 对MetALD新概念的认识以及相关药物研究进展[J]. 肝脏, 2025, 30(1): 7-9.
[3]	蒋程程, 董鑫园. 细胞角蛋白-19、CA50联合甲胎蛋白对肝细胞癌的疾病进展评估价值[J]. 肝脏, 2025, 30(1): 50-54.
[4]	孟纯, 周文娟, 沈预程. TGF-β1、Ca²⁺和BALP联合检测对HCC骨转移患者的评估价值[J]. 肝脏, 2025, 30(1): 55-60.
[5]	丁剑波, 李丽, 李秀惠. 青少年学生血尿酸水平与非酒精性脂肪性肝病发生、发展的关系[J]. 肝脏, 2025, 30(1): 87-90.
[6]	冯巩, 宋娟娟, 尤帅泓, 马晓汇, 严琴琴, 樊亚菲, 弥曼. 儿童乳糜泻与MAFLD研究进展与展望[J]. 肝脏, 2025, 30(1): 136-139.
[7]	秦慧敏, 王晓霖. 误诊为白血病的酒精性肝病相关肝衰竭合并白细胞升高1例[J]. 肝脏, 2025, 30(1): 143-145.
[8]	陈元莉, 曾德锋, 范会文. 超声造影联合超声弹性成像对肝细胞癌微血管侵犯的预测价值[J]. 肝脏, 2024, 29(9): 1035-1039.
[9]	朱继兰, 赵霞, 王市伟, 杨蕾. 多参数磁共振成像联合CT动态增强对晚期肝细胞癌免疫治疗疗效的预测价值[J]. 肝脏, 2024, 29(9): 1040-1046.
[10]	秦锶伟, 朱晓强, 许磊磊, 骆馨. TACE联合索拉非尼与TACE联合¹²⁵I粒子植入治疗肝细胞癌合并门静脉癌栓和动静脉瘘的比较[J]. 肝脏, 2024, 29(9): 1052-1055.
[11]	杨紫郡, 杨佳欣, 郭莉莉. DCE-MRI联合CT增强扫描在肝细胞癌TACE治疗效果评估中的价值[J]. 肝脏, 2024, 29(9): 1060-1063.
[12]	王国峰, 贾玉清, 束长新, 蔡晓东, 王洪勃, 徐件红. 不同入路下行开腹解剖性肝脏切除术治疗肝细胞癌的临床对比[J]. 肝脏, 2024, 29(9): 1064-1067.
[13]	朱洪江, 王连峰. 免疫治疗肝肉瘤样癌1例[J]. 肝脏, 2024, 29(9): 1160-1161.
[14]	李澳忠, 万静之, 李雪梅, 康萌, 刘启玲, 王佳, 秦绪军. 自噬在酒精性肝病中作用及机制研究进展[J]. 肝脏, 2024, 29(8): 891-895.
[15]	黄震霆, 徐小萍, 吴静. 从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病的命名讨论[J]. 肝脏, 2024, 29(8): 900-904.